The advantages of drinking mineral water in the rehabilitation of patients with viral hepatitis C with accompanying non-alcoholic fatty liver disease after suffering from COVID-19
More details
Hide details
State Institute Ukrainian Research Institute of Medical Rehabilitation and Resort Therapy of the Ministry of Health, Odesa, Ukraine
Military Clinical Hospital No. 1 with Polyclinic, Independent Public Health Care Unit, Lublin, Poland
Odesa National Medical University, Odesa, Ukraine
Corresponding author
Lidia Sierpińska   

Military Clinical Hospital No. 1 with Polyclinic, Independent Public Health Care Unit, Lublin, Poland, Al. Racławickie 23, Al. Racławickie 23, 20-049, Lublin, Poland
Ann Agric Environ Med. 2023;30(2):266-272
Introduction and objective:
Past COVID-19 significantly worsens Chronic viral hepatitis C patients with concomitant NAFLD. The aim of the study was to assess effectiveness of including mineral water in the rehabilitation complex in patients with chronic hepatitis C with concomitant non-alcoholic fatty liver disease who contracted COVID-19.

Material and methods:
71 patients with chronic hepatitis C with concomitant NAFLD wo contracted COVID-19 were examined. Group I (control) – 39 patients prescribed dietary nutrition and exercise therapy. Group II (main) – 32 patients, in addition to the above, received packaged ‘Shayanskaya’ mineral water. Methodology comprised anamnestic, anthropometric and clinical, general clinical, biochemical, serological, and molecular genetic (markers of hepatitis C virus, HCV RNA PCR (qualitative and quantitative determination, genotyping), enzyme-linked immunosorbent assay, ultrasonographic examination of digestive organs, and statistical methods.

Due to the treatment, there were significant improvements in carbohydrate and lipid metabolism, as well as the cytokine profile.

The effectiveness was established of the use of silicon low-mineralized bicarbonate sodium mineral water in the complex rehabilitation of patients with chronic hepatitis C and suputor NAFLD after contracted COVID-19. There was a significant improvement in the clinical course of the disease and improvement in the functional state of the liver.

Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol. 2021;27(2):246–256.
Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastoenterol. 2022;28(14):1405–1429.
Drysdale K, Rance J, Cama E, et al. What is known about the care and support provided for an ageing population with lived experience of chronic viral hepatitis as they near end-of-life: A scoping review. Health Soc Care Community. 2022;30(6):E3775–E3788.
Izha G, Dragomiretska N, Gushcha S, et al. Features of clinical, biochemical, and sonographic parameters in patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease. Ann Agric Environ Med. 2023;30(1):49–54.
Lazarus JV, Mark HE, Villota-Rivas M, et al. NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol. 2022;76(4):771–780.
Tian H, Zhang K, Hui Z, et al. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019. Clin Res Hepatol Gastroenterol. 2023;47(1):102068.
Almomani A, Kumar P, Onwuzo S, et al. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States:a population-based study and review of literature. J Gastroenterol Hepatol. 2022;38(2):269–273.
Bhandari P, Sapra A, Ajmeri MS, et al. Nonalcoholic fatty liver disease: could it be the next medical tsunami? Cureus. 2022;14(4):e23806.
Spearman CW, Aghemo A, ValentiL, et al. COVID-19 and the liver: A 2021 update. Liver Int. 2021;41(9):1988–1998.
Wang M, Yan W, QiW, et al. Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatol Int. 2020;14(5):723–732.
Elnaggar M, Abomhya A, Elkhattib I, et al. COVID-19 and liver diseases, what we know so far. World J Clin Cases. 2022;10(13):3969–3980.
Dragomiretska NV, Shevchenko NA, Izha AN, et al. Application of natural and physical factors is in treatment of patients with chronic viral hepatitis of ? – ground of the use. J Health Sci. 2013;3(4):153–163.
Izha G, Dragomiretska N, Gushcha S, et al. Clinical and experimental substantiation of the use of bentonite suspension in the complex rehabilitation of patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease. Balneo Res J. 2020;11(4):472–476.
Babov K, Nikipelova O, Sydorenko O, et al. Grounds for the establishment of a state-owned resort on the territory of the city of Morshyn, Lviv region, Ukraine. Ecological Questions. 2021;32(1):1–15.
Murakami S, Goto Y, Ito ?, et al. The Consumption of bicarbonate-rich mineral water improves glycemic control. Evid Based Complement Alternat Med. 2015;2015:ID 824395. URL.
Gushcha SG, Kucherenko MP, Nasibullin BA, et al. ?ssessment of the influence of natrium chloride water on the course of toxic liver damage in the experiment. PhOL – PharmacologyOnLine. 2021;3:698–706. https://pharmacologyonline.sil....
Quattrini S, Pampaloni B, Brandi ML. Natural mineral waters: chemical characteristics and health effects. Clin Cases Miner Bone Metab. 2016;13(3):173–180.
Costantino ?, Izzo V, Conti V, et al. Sulphate mineral waters: A medical resource in several disorders. Journal of Traditional and Complementary Medicine. 2020;10(4):320–326.
Izha HN, Dragomiretska NV, Nasibullin BA, et al. Clinical and experimental substantiation of the use of mineral water in the treatment of patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease. Herald Marine Med. 2020;2:98–108.
Gozhenko ?, Badiuk N, Nasibullin ?, et al. The role of macronutrients in the implementation of the corrective effect of low-mineralized water in experimental metabolic syndrome. Rocz Panstw Zakł Hig. 2020;71(4):423–430.
Goryachkovsky AM. Clinical biochemistry in laboratory diagnostics. Odessa: Ecology; 2005. p. 616.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fastingplasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529–530.¬....
Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–574.
de-Madaria E, Siau K, Cardenas-Jaen K. Increased amylase and lipase in patient with COVID-19 pneumonia: don’tblame the pancreas just yet! Gastroenterology. 2021;160(5):1871.
Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Chin J Hepatol. 2020;28(2):100–106.
Wu J, Song S, Cao HC, et al. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J. Gastroenterol. 2020;26(19):2286–2293.
Hwang SM, Na BJ, Jung Y, et al. Clinical and laboratory findings of middle east respiratory syndrome Coronavirus Infection. Jpn J Infect Dis. 2019;72:160–167.
Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of middle east respiratory syndrome coronovirus (MERS-CoV) infection – clinicopathological and ultrastructural study. Histopathol. 2018;72:516–524.
Fadeyenko GD, Kushnir IE, Chernova VM, et al. Pathogenetic role of visceral adipose tissue in the development of non-alcoholic fatty liver disease in patients with metabolic syndrome. Modern Gastroenterol. 2018;3:29–36.
Komshilova KA, Troshina EA, Ershova EV, et al. Adiponectin and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity. Therapeutic Archive. 2014;86(10):27–32. https://pubmed.ncbi.nlm.nih.go....
Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyper-insulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34(4):738–744.
Zhernov VA, Frolkov VK, Zubarkina MM. The mechanisms underlying the therapeutic effects of reflexotherapy and drinking mineral waters in the patients presenting with metabolic syndrome. Vopr Kurortol Fizioter Lech Fiz Kult. 2017;94(2):36–41.
Costa-Vieira D, Monteiro R, Martins MJ. Metabolic syndrome features: is there a modulation role by mineral water consumption? A review. Nutrients. 2019;11(5):1141.
Gushcha S, Dragomiretska N, Zabolotna I, et al. Possibilities of using natural mineral waters in the treatment of patients with non-alcoholic fatty liver disease. Balneo Research Journal. 2019;10(4):450–456.
De Meyts P. The Insulin receptor and its signal transduction network. [Updated 2016 Apr 27]. In: Feingold KR, Anawalt B, Blackman MR, et al. Endotext [Internet]. South Dartmouth (MA):, Inc.; 2000.
Dragomiretska N, Babov K, Gushcha S. et al. Application of mineral waters in the complex treatment of patients with gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2020;66(3):225–237.
Zabolotna IB, Gushcha SG, Mikhailenko VL. Non-alcoholic fatty liver disease and mineral waters of Ukraine – opportunities of application (experimental-clinical studies). Balneo Res J. 2018;9(3):270–276.
Zolotarova NA, Solomko OV. Side effects correction in combined lipid-correcting therapy with statins and fibrates using low-mineralized mineral water. World Med. Biol. 2020;4(74):53–58.
Nasibullin BA, Gushcha SG, Dragomiretska NV, et al. Research of the effectiveness of the influence of mineral silicon-sodium chloride water on the course of the pathology of the gastrointestal tract in the experiment. PhOL–PharmacologyOnLine. 2021;2:768–775. https://pharmacologyonline.sil....
Gravina AG, Romeo M, Pellegrino R, et al. Just drink a glass of water? Effects of bicarbonate-sulfate-calcium-magnesium water on the gut-liver axis. Front Pharmacol. 2022;13.869446.
Journals System - logo
Scroll to top